{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:25:03Z","timestamp":1784586303904,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This systematic review aims to evaluate the clinical effectiveness of tumor necrosis factor (TNF) inhibitors in treating monogenic hereditary recurrent fevers (HRFs) in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive literature search across MEDLINE, EMBASE, and Scopus up to May 2024, including case reports, case series, and observational studies involving pediatric patients with HRFs treated with TNF inhibitors. Articles were screened and selected based on PRISMA guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven pediatric cases were identified from ten studies, including patients with FMF (n=2), MKD\/MKD (n=5), TRAPS (n=2), and CAPS (n=2). Etanercept was the most frequently used TNF inhibitor (10\/11 cases), and infliximab was used in one FMF case. Follow-up duration ranged from 3 months to 4 years. Clinical responses varied: full remission in TRAPS cases; partial improvement in some MKD and CAPS cases; and no significant effect in several FMF and MKD\/MKD patients. Etanercept showed the best outcomes in TRAPS, while responses in CAPS and MKD\/MKD were inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>TNFi may offer a therapeutic option for selected pediatric HRF cases, particularly colchicine-resistant FMF with articular symptoms or where IL-1 blockers are unavailable. However, their efficacy appears limited and variable across HRF subtypes. Larger studies are needed to better define the role of TNF inhibitors in pediatric HRFs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1710180","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:05:25Z","timestamp":1763370325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of \u201ctumor necrosis factor inhibitors\u201d in monogenic hereditary recurrent fevers in children and adolescents: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Rim","family":"Dhahri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Boussaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna Ben","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insaf","family":"Fenniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Ben Ayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaoula","family":"Zouaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Rekik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Amri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im\u00e8ne","family":"Gharsallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3777","article-title":"The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation","volume":"18","author":"Manthiram","year":"2017","journal-title":"Nat Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.174","article-title":"A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin","volume":"10","author":"Ozen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00253","article-title":"Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management","volume":"8","author":"Ozen","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200209000-00002","article-title":"The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder","volume":"81","author":"Hull","year":"2002","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-010-0109-z","article-title":"Inflammasome and IL-1\u03b2-mediated disorders","volume":"362","author":"Hoffman","year":"2010","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/annrheumdis-2014-206580","article-title":"Evidence-based provisional classification criteria for autoinflammatory periodic fevers","volume":"74","author":"Gattorno","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever registry and a literature review","volume":"72","author":"Ter Haar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel250","article-title":"Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever","volume":"45","author":"Y\u00fcksel","year":"2006","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2022.0090","article-title":"A rare autoinflammatory disorder in a pediatric patient with favorable response to etanercept: sideroblastic anemia with B cell immunodeficiency, periodic fevers, and developmental delay syndrome","volume":"35","author":"Kisla Ekinci","year":"2022","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3293-2","article-title":"Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents","volume":"35","author":"Eroglu","year":"2015","journal-title":"Rheumatol Int"},{"key":"B12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions","volume":"6","author":"Liberati","year":"2009","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"B16","article-title":"Searching for and selecting studies","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 6.3","author":"Lefebvre","year":"2022"},{"key":"B17","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 6.3","author":"Higgins","year":"2022"},{"key":"B18","article-title":"Collecting data","volume-title":"Cochrane handbook for systematic reviews of interventions. Version 6.3","author":"Li","year":"2022"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1091336","article-title":"Single-cell transcriptomic analysis in two patients with rare systemic autoinflammatory diseases treated with anti-TNF therapy","volume":"14","author":"Hua","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"249\u221251","DOI":"10.1007\/s00296-009-1322-8","article-title":"Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome","volume":"32","author":"Shendi","year":"2012","journal-title":"Rheumatol Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2645\u221251","DOI":"10.1002\/art.11218","article-title":"Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome","volume":"48","author":"Takada","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1317\u221220","DOI":"10.1007\/s10067-008-0911-3","article-title":"Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up","volume":"27","author":"Topalo\u011flu","year":"2008","journal-title":"Clin Rheumatol"},{"key":"B23","first-page":"791\u22122","article-title":"Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever","volume":"22","author":"Marchetti","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"207\u221212","DOI":"10.1007\/s00296-009-0937-0","article-title":"Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment","volume":"30","author":"Morbach","year":"2009","journal-title":"Rheumatol Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2898553","DOI":"10.1155\/2022\/2898553","article-title":"The efficacy of anti-tumor necrosis factor therapy in cryopyrin-associated periodic syndromes: A report of two cases","volume":"2022","author":"Tahghighi","year":"2022","journal-title":"Case Rep Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"146\u22127","DOI":"10.1002\/art.20920","article-title":"Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis","volume":"53","author":"Daysal","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B27","doi-asserted-by":"publisher","first-page":"415\u221230","DOI":"10.1007\/s00247-019-04536-9","article-title":"Autoinflammatory diseases in childhood, part 1: monogenic syndromes","volume":"50","author":"Navallas","year":"2020","journal-title":"Pediatr Radiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0997-25","article-title":"A candidate gene for familial Mediterranean fever","volume":"17","author":"Bernot","year":"1997","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200672","article-title":"Familial Mediterranean fever: prevalence, penetrance and genetic drift","volume":"9","author":"Gershoni-Baruch","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90167-2","article-title":"Familial Mediterranean fever: a survey of 470 cases and review of the literature","volume":"43","author":"Sohar","year":"1967","journal-title":"Am J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2018.02.005","article-title":"La fi\u00e8vre m\u00e9diterran\u00e9enne familiale","volume":"39","author":"Georgin-Lavialle","year":"2018","journal-title":"Rev Med Interne"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200549","article-title":"An international registry on autoinflammatory diseases: the Eurofever experience","volume":"71","author":"Toplak","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-1434","article-title":"Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement","volume":"119","author":"Kallinich","year":"2007","journal-title":"Pediatrics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/0929867323666151117121706","article-title":"Colchicine, biologic agents and more for the treatment of Familial Mediterranean Fever: the old, the new, and the rare","volume":"23","author":"Portincasa","year":"2016","journal-title":"Curr Med Chem"},{"key":"B35","article-title":"Non-response to colchicine in FMF: definition, causes and suggested solutions","volume":"26","author":"Ben-Chetrit","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2016.10.007","article-title":"A position for tumor necrosis factor inhibitors in the management of colchicine-resistant familial Mediterranean fever","volume":"180","author":"Rigante","year":"2016","journal-title":"Immunol Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0463-2","article-title":"Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature","volume":"21","author":"Ozgocmen","year":"2011","journal-title":"Mod Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.berh.2020.101529","article-title":"Systemic autoinflammatory diseases: Clinical state of the art","volume":"34","author":"Georgin-Lavialle","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.04.011","article-title":"Evidence-based recommendations for the practical management of Familial Mediterranean Fever","volume":"43","author":"Hentgen","year":"2013","journal-title":"Semin Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0049-0172(97)80007-8","article-title":"Seronegative spondyloarthropathy in familial Mediterranean fever","volume":"27","author":"Langevitz","year":"1997","journal-title":"Semin Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/BF02030357","article-title":"Ankylosing spondylitis: an unusual manifestation of familial Mediterranean fever. Report of a case complicated by amyloidosis and polyneuropathy","volume":"8","author":"Knockaert","year":"1989","journal-title":"Clin Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e318277083b","article-title":"Efficacy and safety of biologic treatments in Familial Mediterranean Fever","volume":"346","author":"Akgul","year":"2013","journal-title":"Am J Med Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215048","article-title":"Classification criteria for autoinflammatory recurrent fevers","volume":"78","author":"Gattorno","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1710180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:05:27Z","timestamp":1763370327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1710180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1710180"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1710180","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1710180"}}